Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
Second Military Medical University · Eastern Hepatobiliary Surgery Hospital · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
118
total citations
- FWCI
- 37.62
- Percentile
- 100%
- References
- 58
Citations per year
Authors
20- KWKang Wang
Second Military Medical University, Eastern Hepatobiliary Surgery Hospital
- YXYan‐Jun Xiang
Second Military Medical University, Eastern Hepatobiliary Surgery Hospital
- HYHongming Yu
Second Military Medical University, Eastern Hepatobiliary Surgery Hospital
- YCYuqiang Cheng
Second Military Medical University, Eastern Hepatobiliary Surgery Hospital
- ZLZong‐Han Liu
Second Military Medical University, Eastern Hepatobiliary Surgery Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Clinical endpoint
- Internal medicine
- Hazard ratio
- Hepatocellular carcinoma
- Adjuvant
- Adverse effect
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.